Navigation Links
Pharmasset to Present at Lazard Capital Markets Healthcare Conference
Date:11/9/2009

PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Sixth Annual Lazard Capital Markets Healthcare Conference. The conference will be held at the St Regis Hotel in New York City (November 17-19, 2009).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Wednesday, November 18, 2009 at 3:45 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following each presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, has completed initial Phase 1 clinical studies which provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys(®) and Copegus(® )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
2. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
3. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
4. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
5. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
6. Pharmasset Reports Fiscal Year End 2008 Financial Results
7. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... “Now Hiring!” is a popular ... The company has achieved record-breaking sales for over 30 consecutive years and now ... months. , The upcoming year offers excitement and growth at HDIS, following the company’s ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative ... their partnership to provide the Pharmacist eCare Plan to Computer-Rx pharmacies ... country with the ability to develop the Pharmacist eCare Plan, a shared document ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Donna Bergman, professor ... co-authored and published an article in the medical science journal Physical Medicine and ... the article and the research that helped produce it, were written and conducted ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... Facing medical ... father Ezra Clark is taking advantage of a new benefit for employees that is ... means a lot that the company supports me and other employees as new parents. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University ... it produces the same kind of electrical energy that the body uses. , ... moving electrons. This flow of electrons out of the battery is generated by moving ...
Breaking Medicine News(10 mins):